Half-Year 2022 Financial and Clinical Trials Update
Pharma Division CER sales growth¹ in %
Top 20 products by region
Roche
US
Europe
Q3
Q4 Q1
Q2
Q3
Q4
Q1 Q2
Q3
Japan
Q4
International
Q1 Q2
Q3 Q4 Q1 Q2
Ocrevus
0
23
12
10
36
26 34 34
35
51 29 62
Perjeta
2
-2
-1
4
-8
-8
-21
-12
0 -3 -1
Hemlibra
36
33
28
24
26
53
31
29
Tecentriq
10
2
10
15
16
41
14 24
Actemra/RoActemra
143
67 22
-31
10
18
-4 -2
Herceptin
-52 -34
-26 -29
-20
-3
-13 -9
2225
29 30 15 24
75 34 -5 -9
-37 -36 -30 -27
Avastin
-50
-45 -39 -36
MabThera
-49
-32 -20 -24
Kadcyla
0
3
Xolair
8
14
Alecensa
9
18
32001
-69
-49 -56 -49
5
LO
-33
-13
-19 -16
-1
16
16
8 12
550
TE523222
-1
16
24
32 37
138
55
63 115
62
24
0 17
5 12 -2
-14
-55
-30 -44
-7
17
-18 -3
222
-30
0 -12 -13
-17 -15
59 42 28
-11 -24 -23 -17
13
25
14
7
9
5
80
11
LO
FLO
LO
Ronapreve
-
-61
-99
-2
-25 -15
-23 -13
20
16
38 26 81
7
5
40
25
45
29
-68
៩៤
3778
25
280
Lucentis
-10
2
-26
-9
1
TNKase/Activase
2 *
22
-21
1
17
7 -3
4
Evrysdi
112
36
28
227
*
*
-5
Esbriet
-2
-7 -4
-28
0
0
-5
1
-73
-36
-36 -36
Gazyva
3 *
11
0
3
10
2
-5
-8
10
-7
8 -10
43
56 75
101
Phesgo
236 187
134
*
*
*
188
278
Pulmozyme
-10
6
0
5
-10
-15
-11
-12
-18
CellCept
-18
-31
-15
-17
-2
3
-7
-7
292
22 11 44
-7 -9 -8 -9
18
=
12
22
45
13
w&
-4
14
3
-14
3
CER = Constant Exchange Rates; * over 500%; 1Q3-Q4/21 vs Q3-Q4/20; Q1-Q2/22 vs Q1-Q2/21
168View entire presentation